These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. An industry perspective on the monitoring of subvisible particles as a quality attribute for protein therapeutics. Singh SK; Afonina N; Awwad M; Bechtold-Peters K; Blue JT; Chou D; Cromwell M; Krause HJ; Mahler HC; Meyer BK; Narhi L; Nesta DP; Spitznagel T J Pharm Sci; 2010 Aug; 99(8):3302-21. PubMed ID: 20310025 [TBL] [Abstract][Full Text] [Related]
3. Subvisible (2-100 μm) particle analysis during biotherapeutic drug product development: Part 2, experience with the application of subvisible particle analysis. Corvari V; Narhi LO; Spitznagel TM; Afonina N; Cao S; Cash P; Cecchini I; DeFelippis MR; Garidel P; Herre A; Koulov AV; Lubiniecki T; Mahler HC; Mangiagalli P; Nesta D; Perez-Ramirez B; Polozova A; Rossi M; Schmidt R; Simler R; Singh S; Weiskopf A; Wuchner K Biologicals; 2015 Nov; 43(6):457-73. PubMed ID: 26324466 [TBL] [Abstract][Full Text] [Related]
4. Quantitation of protein particles in parenteral solutions using micro-flow imaging. Huang CT; Sharma D; Oma P; Krishnamurthy R J Pharm Sci; 2009 Sep; 98(9):3058-71. PubMed ID: 18937372 [TBL] [Abstract][Full Text] [Related]
5. Comparative Evaluation of Two Methods for Preparative Fractionation of Proteinaceous Subvisible Particles--Differential Centrifugation and FACS. Boll B; Folzer E; Finkler C; Huwyler J; Mahler HC; Schmidt R; Koulov AV Pharm Res; 2015 Dec; 32(12):3952-64. PubMed ID: 26195006 [TBL] [Abstract][Full Text] [Related]
6. Pharmaceutical feasibility of sub-visible particle analysis in parenterals with reduced volume light obscuration methods. Hawe A; Schaubhut F; Geidobler R; Wiggenhorn M; Friess W; Rast M; de Muynck C; Winter G Eur J Pharm Biopharm; 2013 Nov; 85(3 Pt B):1084-7. PubMed ID: 23454051 [TBL] [Abstract][Full Text] [Related]
8. Development of a microflow digital imaging assay to characterize protein particulates during storage of a high concentration IgG1 monoclonal antibody formulation. Wuchner K; Büchler J; Spycher R; Dalmonte P; Volkin DB J Pharm Sci; 2010 Aug; 99(8):3343-61. PubMed ID: 20229596 [TBL] [Abstract][Full Text] [Related]
9. Effect of solution properties on the counting and sizing of subvisible particle standards as measured by light obscuration and digital imaging methods. Werk T; Volkin DB; Mahler HC Eur J Pharm Sci; 2014 Mar; 53():95-108. PubMed ID: 24370624 [TBL] [Abstract][Full Text] [Related]
11. Sterile Basics of Compounding: Particulates in Parenteral Preparations: Sources, Minimization, and Detection. Allen LV Int J Pharm Compd; 2022; 26(3):219-228. PubMed ID: 35657746 [TBL] [Abstract][Full Text] [Related]
12. Characterization of Inherent Particles and Mechanism of Thermal Stress Induced Particle Formation in HSV-2 Viral Vaccine Candidate. Li L; Kirkitadze M; Bhandal K; Roque C; Yang E; Carpick B; Rahman N Curr Pharm Biotechnol; 2017 Nov; 18(8):638-647. PubMed ID: 28914197 [TBL] [Abstract][Full Text] [Related]
13. Measurement of subvisible particulates in lyophilised Erwinia chrysanthemi L-asparaginase and relationship with clinical experience. Gervais D; Corn T; Downer A; Smith S; Jennings A AAPS J; 2014 Jul; 16(4):784-90. PubMed ID: 24854894 [TBL] [Abstract][Full Text] [Related]
14. Separation, Characterization and Discriminant Analysis of Subvisible Particles in Biologics Formulations. Akhunzada ZS; Hubert M; Sahin E; Pratt J Curr Pharm Biotechnol; 2019; 20(3):232-244. PubMed ID: 30767738 [TBL] [Abstract][Full Text] [Related]
15. Contribution of Intravenous Administration Components to Subvisible and Submicron Particles Present in Administered Drug Product. Pollo M; Mehta A; Torres K; Thorne D; Zimmermann D; Kolhe P J Pharm Sci; 2019 Jul; 108(7):2406-2414. PubMed ID: 30849460 [TBL] [Abstract][Full Text] [Related]
16. Particulate matter in four reconstituted cephalosporin injections. Kilarski DJ; Visconti JA; Frank SG Am J Hosp Pharm; 1983 Apr; 40(4):619-23. PubMed ID: 6846372 [TBL] [Abstract][Full Text] [Related]
17. Quantification and characterization of subvisible proteinaceous particles in opalescent mAb formulations using micro-flow imaging. Sharma DK; Oma P; Pollo MJ; Sukumar M J Pharm Sci; 2010 Jun; 99(6):2628-42. PubMed ID: 20049937 [TBL] [Abstract][Full Text] [Related]
18. Issues and challenges of subvisible and submicron particulate analysis in protein solutions. Scherer TM; Leung S; Owyang L; Shire SJ AAPS J; 2012 Jun; 14(2):236-43. PubMed ID: 22391789 [TBL] [Abstract][Full Text] [Related]
19. The use of flow cytometry for the detection of subvisible particles in therapeutic protein formulations. Mach H; Bhambhani A; Meyer BK; Burek S; Davis H; Blue JT; Evans RK J Pharm Sci; 2011 May; 100(5):1671-8. PubMed ID: 21374606 [TBL] [Abstract][Full Text] [Related]